SAKK 38/19: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=260 | Active, not recruiting | Sponsor: Swiss Cancer Institute | Trial primary completion date: Jul 2026 ➔ Jan 2029
Circulating tumor DNA • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|